Tern PLC (GB00BFPMV798)
XSTU 
NASDAQ (NGS) Primary XSTU Summary
GB00BFPMV798 Chart
Merck to acquire Terns Pharmaceuticals for $6.7B
Merck & Co Inc (NYSE:MRK, XETRA:6MK) announced on Wednesday that it will acquire US biotech firm Terns Pharmaceuticals (NASDAQ:TERN) for $53 per share in cash, valuing the company at approximately $6.7 billion. This marks Merck's third multibillion-dollar acquisition in the past year as the company looks to strengthen its portfolio ahead of its top-selling cancer drug Keytruda losing patent protection in 2028.
Terns Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:TERN)
Terns Pharmaceuticals, Inc. (NASDAQ: TERN - Get Free Report) was the target of unusually large options trading on Friday. Traders bought 9,767 call options on the stock. This represents an increase of 501% compared to the typical volume of 1,624 call options. Terns Pharmaceuticals Price Performance NASDAQ: TERN opened at $46.52 on Friday. The business has a
Wall Street Analysts See a 50.91% Upside in Terns Pharmaceuticals (TERN): Can the Stock Really Move This High?
The consensus price target hints at a 50.9% upside potential for Terns Pharmaceuticals (TERN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Tern PLC (GB00BFPMV798) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Tern PLC ever had a stock split?
Tern PLC Profile
| Biotechnology Industry | Healthcare Sector | Amy L. Burroughs CEO | XSTU Exchange | US8808811074 ISIN |
| US Country | 59 Employees | - Last Dividend | - Last Split | 5 Feb 2021 IPO Date |
Overview
Terns Pharmaceuticals, Inc. is a trailblazer in the field of biopharmaceuticals, focusing primarily on the clinical-stage development of small-molecule product candidates. These candidates are targeted at a variety of critical areas, including oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Established in 2016 and with its headquarters located in Foster City, California, Terns Pharmaceuticals is on a mission to bring innovative and effective treatments to patients suffering from these complex conditions.
Products and Services
TERN-701 - As an allosteric BCR-ABL tyrosine kinase inhibitor (TKI), TERN-701 distinguishes itself by being in phase 1 clinical trial for the treatment of chronic myeloid leukemia (CML). This form of cancer begins in the bone marrow, and TERN-701 represents a promising avenue for patients battling this condition, aiming to offer a novel treatment pathway that could significantly impact patient care.
TERN-501 - With its unique position as a thyroid hormone receptor beta agonist, TERN-501 showcases enhanced liver distribution and metabolic stability. Currently in a Phase IIa clinical trial, TERN-501 is designed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). This illustrates Terns Pharmaceuticals' commitment to addressing complex liver diseases and their potential complications through innovative therapeutic strategies.
TERN-601 - TERN-601 is a pioneering effort in the battle against obesity, a small-molecule Glucagon-Like Peptide-1 receptor agonist program. Enticingly, this program is aimed at an oral administration route, a feature that could significantly enhance patient compliance and ease of use. Still in development, TERN-601 represents the company’s forward-thinking approach to offering new solutions for managing and potentially overcoming obesity.
